VISN 19 Gene Expression Oncology Testing

THIS IS A SOURCES SOUGHT NOTICE ONLY. THIS IS NOT A REQUEST FOR PROPOSAL. The Department of Veterans Affairs, VHA, Network Contracting Office (NCO) 19 Rocky Mountain Acquisition Center is seeking potential sources that are capable of providing Oncotype Genetic (Gene Expression) Reference Lab Testing Services that includes but is not limited to: specimen preparation and storage; transportation of clinical laboratory specimens; performance of analytical testing; reporting of analytical test results; and consultative services. The Contractor shall be approved to provide clinical diagnostic laboratory tests under both Medicare and Medicaid regulations and all applicable federal and state laws. The Contractor shall be capable of providing the following gene expression tests (OR EQUIVALENT): a) Oncotype DX Breast Recurrence Score Assay (81519); b) Oncotype DX Breast DCIS Score Assay (0045U); c) Oncotype DX Colon Recurrence Score Assay (81525): d) Oncoguard Liver CPT (81599); e) OncoExtra (0329U); and f) Cologuard CPT (81528) This requirement is for the following VA Medical Centers: Rocky Mountain Regional VA Medical Center, 1700 N. Wheeling St, Aurora, CO, 80045 VA Montana Health Care System, 3687 Veterans Dr., Fort Harrison, MT 59636 Oklahoma City VA Health Care System, 921 NE 13th St, Oklahoma City, OK, 74104 Salt Lake City VA Health Care System, 500 Foothill Drive, Salt Lake City, Ut 84148 NCO 19 is performing market research to determine if there is a sufficient number of qualified (1) Service-Disabled Veteran-Owned Small Business (SDVOSB); (2) Veteran-Owned Small Business (VOSB); (3) Small or emerging small business firms; or (4) Large businesses who can fulfill the requirement. This Sources Sought notice is issued for the purpose of market research in accordance with Federal Acquisition Regulation (FAR) Part 10. All SDVOSB, VOSB, small and large businesses capable of fulfilling the requirement are invited to respond. Any information submitted by respondents to this sources sought synopsis is voluntary. This sources sought notice is not to be construed as a commitment by the Government, nor will the Government reimburse any costs associated with the submission of information in response to this notice. Respondents will not individually be notified of the results of any Government assessments. Responses and questions may be submitted electronically to: Juanita.Street@va.gov and NCO19Lab@va.gov a Microsoft word compatible format no later than Wednesday, November 12th at 10:00am Mountain Time. PHONE CALLS NOT ACCEPTED. NAICS code to be used for this acquisition is 621511. All interested firms who can MEET and FULFILL the requirements stated in the Summary of Requirements below should respond, in writing, with the following information: Company Name: Address: UEI (Unique Entity ID) Number: Contact Name: Phone No.: Email: Business Size Information - Select all that applies: Small Business Emerging Small Business Small Disadvantaged Business Certified under Section 8(a) of the Small Business Act HUBZone Woman Owned Certified Service-Disabled Veteran Owned Small Veteran Owned Small Business Large Business Is your Company a FSS/GSA Contract Holder: Yes No Enter your Company s FSS/GSA Contract Number: Enter the Effective Date/ Expiration Date of FSS/GSA Contract: Are the proposed Genetic Oncology testing services listed and available on the above FSS/GSA Contract: Yes No Questions for Small Businesses ONLY: Limitations on Subcontracting (FAR 52.219-14) What percentage of the work would be subcontracted to another company? ________ If > 0, what is company s business size: __________ If subcontracting, what added value do you offer (FAR 52.215-23): _______________________________ Offerors capable of providing the Gene Expression Oncology tests or equivalent tests, please complete the table above and send your responses via email to Juanita.Street@va.gov and NCO19Lab@va.gov in a Microsoft word compatible format no later than Wednesday, November 12th, 10:00am Mountain Time. PHONE CALLS NOT ACCEPTED.